ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,3773
0,01%
Bitcoin
66.160,26
0,24%
Brent Oil
82,275
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Outlook Therapeutics Inc (OTLKW)

  7. Outlook Therapeutics Inc (OTLKW) Notícias

OTLKW

Outlook Therapeutics (OTLKW)

Outlook Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OTLKW
DataHoraFonteTítuloCódigoCompanhia
11/06/202410:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Virtual Investor Pitch ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
28/05/202409:05GlobeNewswire Inc.Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
15/05/202418:00GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
13/05/202409:50GlobeNewswire Inc.Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
09/05/202409:45GlobeNewswire Inc.Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastNASDAQ:OTLKWOutlook Therapeutics Inc
02/05/202410:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Retina World Congress 2024NASDAQ:OTLKWOutlook Therapeutics Inc
29/04/202410:00GlobeNewswire Inc.Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseNASDAQ:OTLKWOutlook Therapeutics Inc
15/04/202417:15GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionNASDAQ:OTLKWOutlook Therapeutics Inc
22/03/202408:35GlobeNewswire Inc.Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
18/03/202418:10GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionNASDAQ:OTLKWOutlook Therapeutics Inc
12/03/202409:05GlobeNewswire Inc.Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitNASDAQ:OTLKWOutlook Therapeutics Inc
14/02/202410:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
31/01/202410:05GlobeNewswire Inc.Outlook Therapeutics® Doses First Subject in NORSE EIGHTNASDAQ:OTLKWOutlook Therapeutics Inc
23/01/202410:00GlobeNewswire Inc.Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
22/12/202310:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EUNASDAQ:OTLKWOutlook Therapeutics Inc
19/12/202310:05GlobeNewswire Inc.Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
06/12/202310:05GlobeNewswire Inc.Outlook Therapeutics® Announces Strategic Organizational RealignmentNASDAQ:OTLKWOutlook Therapeutics Inc
27/11/202310:05GlobeNewswire Inc.Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
14/11/202310:05GlobeNewswire Inc.Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of EuropeNASDAQ:OTLKWOutlook Therapeutics Inc
02/11/202309:05GlobeNewswire Inc.Outlook Therapeutics® Provides Update on Type A Meetings with FDANASDAQ:OTLKWOutlook Therapeutics Inc
01/11/202309:05GlobeNewswire Inc.Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
29/09/202309:05GlobeNewswire Inc.Outlook Therapeutics® Requests Type A Meeting With FDANASDAQ:OTLKWOutlook Therapeutics Inc
21/09/202309:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
05/09/202309:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
30/08/202307:00GlobeNewswire Inc.Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
14/08/202309:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term MilestonesNASDAQ:OTLKWOutlook Therapeutics Inc
01/08/202309:45GlobeNewswire Inc.Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023NASDAQ:OTLKWOutlook Therapeutics Inc
16/05/202308:10Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:OTLKWOutlook Therapeutics Inc
16/05/202307:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OTLKWOutlook Therapeutics Inc
15/05/202309:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:OTLKW

Seu Histórico Recente

COIN
SKEYETH
SmartKey
ASX
RT1HA
Resimac Triomphe
BIT
P1XC92
NLBNPIT1XC92 20240920 2.8
BIT
P20AO2
NLBNPIT20AO2 20240621 2600
BIT
NSCIT9586560
Intesa Sanpaolo
COIN
FNBUSD
FNB Token
LSE
MAEA
BIT
S28949
Societe Generale Effekten
BIT
P1JNA5
BNP Paribas Issuance BV
BIT
WSIAV25
Siav
BIT
P1TXK2
BNP Paribas Issuance
BIT
P1I3U5
BNP Paribas Issuance
BIT
P1SS75
BNP Paribas Issuance
NASDAQ
BHIMX
Brigade High Income Fund...
EU
3SLV
Graniteshares 3x Short L...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados